文献速递血栓与止血

CATCH研究中因静脉血栓栓塞接受治疗的癌症患者临床相关出血情况

Clinically relevant bleeding in cancer patients treated for venous thromboembolism from the CATCH study.
PubMed 文献 · J Thromb Haemost · 2018-04-17

CATCH试验的预设二次分析纳入900例活动性癌症合并急性症状性静脉血栓栓塞患者,比较亭扎肝素与华法林治疗6个月的临床相关出血(CRB)。138例(15.3%)发生180次CRB事件,亭扎肝素组60例81次,华法林组78例99次(HR 0.64,95%CI 0.45-0.89)。多因素分析显示年龄>75岁和颅内恶性肿瘤为CRB危险因素。

要点

  • 癌症合并静脉血栓栓塞抗凝治疗中CRB发生率为15.3%(138/900例)。
  • 亭扎肝素组CRB 60例81次 vs 华法林组78例99次,HR 0.64(95%CI 0.45-0.89)。
  • 年龄>75岁(HR 1.83)和颅内恶性肿瘤(HR 1.97)增加CRB风险。

核心结论

  • CRB是癌症合并静脉血栓栓塞患者抗凝治疗期间的常见并发症,与年龄>75岁和颅内恶性肿瘤相关。
  • 亭扎肝素组CRB风险低于华法林组(HR 0.64,95%CI 0.45-0.89)。

研究设计与样本

  • 随机、开放标签、III期CATCH试验(NCT01130025)的预设二次分析。
  • 纳入900例活动性癌症合并急性症状性静脉血栓栓塞患者。
  • 患者接受亭扎肝素175 IU kg-1每日一次或华法林(目标INR 2.0-3.0)治疗6个月。

主要发现

  • 900例随机患者中138例(15.3%)发生180次CRB事件。
  • 亭扎肝素组60例患者发生81次CRB事件,华法林组78例患者发生99次CRB事件(HR 0.64;95%CI 0.45-0.89)。
  • 常见出血部位为胃肠道(36.7%;n=66)、泌尿生殖道(22.8%;n=41)和鼻部(10.0%;n=18)。
  • 多因素分析显示年龄>75岁(HR 1.83,95%CI 1.14-2.94)和颅内恶性肿瘤(HR 1.97,95%CI 1.07-3.62)增加CRB风险。
  • 华法林组40.4%的CRB事件发生于INR<3.0的患者;治疗窗内时间较低与CRB风险较高相关。

关键数值与推荐

  • CRB发生率:总体15.3%(138/900例)。
  • 亭扎肝素组CRB 60例81次 vs 华法林组78例99次,HR 0.64(95%CI 0.45-0.89)。
  • 年龄>75岁:HR 1.83(95%CI 1.14-2.94)。
  • 颅内恶性肿瘤:HR 1.97(95%CI 1.07-3.62)。
  • 常见出血部位:胃肠道36.7%(n=66)、泌尿生殖道22.8%(n=41)、鼻部10.0%(n=18)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

UNLABELLED: Essentials Cancer patients receiving anticoagulants for venous thromboembolism have an elevated bleeding risk. This secondary analysis of CATCH assessed characteristics of clinically relevant bleeding (CRB). CRB occurs in 15% of cancer patients with thrombosis using therapeutic doses of anticoagulation. After multivariate analysis, risk factors for CRB were age >75 years and intracranial malignancy. SUMMARY: Background Cancer patients with acute venous thromboembolism (VTE) receiving anticoagulant treatment have an increased bleeding risk. Objectives We performed a prespecified secondary analysis of the randomized, open-label, Phase III CATCH trial (NCT01130025) to assess the rate and sites of and the risk factors for clinically relevant bleeding (CRB). Patients/Methods Patients with active cancer and acute, symptomatic VTE received either tinzaparin 175 IU kg-1 once daily or warfarin (target International Normalized Ratio [INR] of 2.0-3.0) for 6 months. Fisher's exact test was used to screen prespecified clinical risk factors; those identified as being significantly associated with an increased risk of CRB then underwent competing risk regression analysis of time to first CRB. Results Among 900 randomized patients, 138 (15.3%) had 180 CRB events. CRB occurred in 60 patients (81 events) in the tinzaparin group and in 78 patients (99 events) in the warfarin group (hazard ratio [HR] 0.64; 95% confidence interval [CI] 0.45-0.89). Common bleeding sites were gastrointestinal (36.7%; n = 66), genitourinary (22.8%; n = 41), and nasal (10.0%; n = 18). In multivariate analysis, the risk of CRB increased with age > 75 years (HR 1.83, 95% CI 1.14-2.94) and intracranial malignancy (HR 1.97, 95% CI 1.07-3.62). In the warfarin group, 40.4% of CRB events occurred in patients with with an INR of < 3.0. A lower time in therapeutic range was associated with a higher risk of CRB. Conclusions CRB is a frequent complication in cancer patients with VTE during anticoagulant treatment, and is associated with age > 75 years and intracranial malignancy.

来源:J Thromb Haemost,查看原文。版权归原作者所有。

引用

  1. Kamphuisen PW, Lee AYY, Meyer G, et al. Clinically relevant bleeding in cancer patients treated for venous thromboembolism from the CATCH study. J Thromb Haemost. 2018. PMID: 29573330. doi:10.1111/jth.14007

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。